Liliana Scorzoni

Prof. Dr. Liliana Scorzoni

te Program in Nursing, Guarulhos, SP, Brazil, University of Guarulhos, Guarulhos, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Journal of Medical Microbiology
Verified
Journal Article
Open access
JSJ. C. O. Sardi
J. C. O. Sardi
Liliana ScorzoniLiliana Scorzoni
Liliana Scorzoni
TBT. Bernardi
T. Bernardi
AFA. M. Fusco-Almeida
A. M. Fusco-Almeida
Maria José Soares Mendes GianniniMaria José Soares Mendes Giannini
Maria José Soares Mendes Giannini
The incidence of fungal infections has increased significantly, so contributing to morbidity and mortality. This is caused by an increase in antimicrobial resistance and the restricted number of antifungal drugs, which retain many side effects. Candida species are major human fungal pathogens that cause both mucosal and deep tissue infections. Recent evidence suggests that the majority of infections produced by this pathogen are associated with biofilm growth. Biofilms are biological communities with a high degree of organization, in which micro-organisms form structured, coordinated and functional communities. These biological communities are embedded in a self-created extracellular matrix. Biofilm production is also associated with a high level of antimicrobial resistance of the associated organisms. The ability of Candida species to form drug-resistant biofilms is an important factor in their contribution to human disease. The study of plants as an alternative to other forms of drug discovery has attracted great attention because, according to the World Health Organization, these would be the best sources for obtaining a wide variety of drugs and could benefit a large population. Furthermore, silver nanoparticles, antibodies and photodynamic inactivation have also been used with good results. This article presents a brief review of the literature regarding the epidemiology of Candida species, as well as their pathogenicity and ability to form biofilms, the antifungal activity of natural products and other therapeutic options.

23 January 2017 in Frontiers in Microbiology
Verified
Journal Article
Open access
Liliana ScorzoniLiliana Scorzoni
Liliana Scorzoni
ASAna C. A. de Paula e Silva
Ana C. A. de Paula e Silva
Caroline MarcosCaroline Marcos
Caroline Marcos
PAPatricia Assato
Patricia Assato
WMWanessa C. M. A. de Melo
Wanessa C. M. A. de Melo
AFAna Marisa Fusco-Almeida
Ana Marisa Fusco-Almeida
The high rates of morbidity and mortality caused by fungal infections are associated with the current limited antifungal arsenal and the high toxicity of the compounds. Additionally, identifying novel drug targets is challenging because there are many similarities between fungal and human cells. The most common antifungal targets include fungal RNA synthesis and cell wall and membrane components, though new antifungal targets are being investigated. Nonetheless, fungi have developed resistance mechanisms, such as overexpression of efflux pump proteins and biofilm formation, emphasizing the importance of understanding these mechanisms. To address these problems, different approaches to preventing and treating fungal diseases are described in this review, with a focus on the resistance mechanisms of fungi, with the goal of developing efficient strategies to overcoming and preventing resistance as well as new advances in antifungal therapy. Due to the limited antifungal arsenal, researchers have sought to improve treatment via different approaches, and the synergistic effect obtained by the combination of antifungals contributes to reducing toxicity and could be an alternative for treatment. Another important issue is the development of new formulations for antifungal agents, and interest in nanoparticles as new types of carriers of antifungal drugs has increased. In addition, modifications to the chemical structures of traditional antifungals have improved their activity and pharmacokinetic parameters. Moreover, a different approach to preventing and treating fungal diseases is immunotherapy, which involves different mechanisms, such as vaccines, activation of the immune response and inducing the production of host antimicrobial molecules. Finally, the use of a mini-host has been encouraging for in vivo testing because these animal models demonstrate a good correlation with the mammalian model; they also increase the speediness of as well as facilitate the preliminary testing of new antifungal agents. In general, many years are required from discovery of a new antifungal to clinical use. However, the development of new antifungal strategies will reduce the therapeutic time and / or increase the quality of life of patients.

1 January 2012 in Frontiers in Microbiology
Verified
Journal Article
Open access
AMAna C. Mesa-Arango
Ana C. Mesa-Arango
Liliana ScorzoniLiliana Scorzoni
Liliana Scorzoni
OZOscar Zaragoza
Oscar Zaragoza
“Amphotericin B acts through pore formation at the cell membrane after binding to ergosterol” is an accepted dogma about the action mechanism of this antifungal, and this sentence is widely found in the literature. But after 60 years of investigation, the action mechanism of Amphotericin B is not fully elucidated. Amphotericin B is a polyene substance that is one of the most effective drugs for the treatment of fungal and parasite infections. As stated above, the first mechanism of action described was pore formation after binding to the ergosterol present in the membrane. But it has also been demonstrated that AmB induces oxidative damage in the cells. Moreover, amphotericin B modulates the immune system, and this activity has been related to the protective effect of the molecule, but also to its toxicity in the host. This review tries to provide a general overview of the main aspects of this molecule, and highlight the multiple effects that this molecule has on both the fungal and host cells.

10 May 2017 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
CCCaroline Costa-Orlandi
Caroline Costa-Orlandi
JSJANAINA DE CÁSSIA ORLANDI SARDI
JANAINA DE CÁSSIA ORLANDI SARDI
NPNayla De Souza Pitangui
Nayla De Souza Pitangui
HOHaroldo C. De Oliveira
Haroldo C. De Oliveira
Liliana ScorzoniLiliana Scorzoni
Liliana Scorzoni
Maria José Soares Mendes GianniniMaria José Soares Mendes Giannini
Maria José Soares Mendes Giannini
Biofilm formation is an important virulence factor for pathogenic fungi. Both yeasts and filamentous fungi can adhere to biotic and abiotic surfaces, developing into highly organized communities that are resistant to antimicrobials and environmental conditions. In recent years, new genera of fungi have been correlated with biofilm formation. However, Candida biofilms remain the most widely studied from the morphological and molecular perspectives. Biofilms formed by yeast and filamentous fungi present differences, and studies of polymicrobial communities have become increasingly important. A key feature of resistance is the extracellular matrix, which covers and protects biofilm cells from the surrounding environment. Furthermore, to achieve cell–cell communication, microorganisms secrete quorum-sensing molecules that control their biological activities and behaviors and play a role in fungal resistance and pathogenicity. Several in vitro techniques have been developed to study fungal biofilms, from colorimetric methods to omics approaches that aim to identify new therapeutic strategies by developing new compounds to combat these microbial communities as well as new diagnostic tools to identify these complex formations in vivo. In this review, recent advances related to pathogenic fungal biofilms are addressed.

27 November 2018 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
TPThaís Pereira
Thaís Pereira
PBPatrícia Pimentel de Barros
Patrícia Pimentel de Barros
LFLuciana Ruano de Oliveira Fugisaki
Luciana Ruano de Oliveira Fugisaki
RRRodnei Dennis Rossoni
Rodnei Dennis Rossoni
FRFelipe de Camargo Ribeiro
Felipe de Camargo Ribeiro
Liliana ScorzoniLiliana Scorzoni
Liliana Scorzoni
The use of invertebrates for in vivo studies in microbiology is well established in the scientific community. Larvae of Galleria mellonella are a widely used model for studying pathogenesis, the efficacy of new antimicrobial compounds, and immune responses. The immune system of G. mellonella larvae is structurally and functionally similar to the innate immune response of mammals, which makes this model suitable for such studies. In this review, cellular responses (hemocytes activity: phagocytosis, nodulation, and encapsulation) and humoral responses (reactions or soluble molecules released in the hemolymph as antimicrobial peptides, melanization, clotting, free radical production, and primary immunization) are discussed, highlighting the use of G. mellonella as a model of immune response to different human pathogenic microorganisms.

28 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Liliana ScorzoniLiliana Scorzoni
Liliana Scorzoni
MLMaría Pilar de Lucas
María Pilar de Lucas
AMAna Cecilia Mesa-Arango
Ana Cecilia Mesa-Arango
AFAna Marisa Fusco-Almeida
Ana Marisa Fusco-Almeida
ELEncarnación Lozano
Encarnación Lozano
OZOscar Zaragoza
Oscar Zaragoza
The incidence of opportunistic fungal infections has increased in recent decades due to the growing proportion of immunocompromised patients in our society. Candida krusei has been described as a causative agent of disseminated fungal infections in susceptible patients. Although its prevalence remains low among yeast infections (2–5%), its intrinsic resistance to fluconazole makes this yeast important from epidemiologic aspects. Non mammalian organisms are feasible models to study fungal virulence and drug efficacy. In this work we have used the lepidopteran Galleria mellonella and the nematode Caenorhabditis elegans as models to assess antifungal efficacy during infection by C. krusei. This yeast killed G. mellonella at 25, 30 and 37°C and reduced haemocytic density. Infected larvae melanized in a dose-dependent manner. Fluconazole did not protect against C. krusei infection, in contrast to amphotericin B, voriconazole or caspofungin. However, the doses of these antifungals required to obtain larvae protection were always higher during C. krusei infection than during C. albicans infection. Similar results were found in the model host C. elegans. Our work demonstrates that non mammalian models are useful tools to investigate in vivo antifungal efficacy and virulence of C. krusei.